PCD Pharma Franchise Opportunities in Delhi with Daksh Diabetes and Cardiac Care
Recent data paints a stark picture of Delhi’s escalating health crisis, establishing the national capital as a major hotspot for diabetes and hypertension in India. The Center for cArdio-metabolic Risk Reduction in South Asia (CARRS) Study found that a staggering 72.7% of Delhi’s adult population has either diabetes or prediabetes, with 25.2% already diagnosed with diabetes and 47.6% in the prediabetes stage. This means nearly three in four adults in Delhi are either diabetic or on the verge of becoming diabetic.
The burden is not limited to diabetes. A 2025 study on hypertension in Delhi found that while the overall prevalence of hypertension was 12.2%, the prevalence of prehypertension was a concerning 54.3%. This indicates that more than half of adults are at immediate risk of developing full-blown hypertension. In rural Delhi, the situation is even more severe, with hypertension prevalence reaching 35.7%. Alarmingly, only 14.6% of those with hypertension had their blood pressure under control, highlighting a massive gap in treatment and management.
Obesity, a key driver of both diabetes and hypertension, has reached epidemic proportions. The National Family Health Survey (NFHS-6) shows that 41.4% of women and over 38% of men in Delhi are overweight or obese. The Economic Survey further revealed that 41.3% of women in Delhi are obese compared to 38% of men. This obesity crisis, combined with high-income levels, sedentary lifestyles, and poor dietary habits, is fueling the rapid rise of non-communicable diseases. NCDs already account for a significant portion of deaths in the capital, with circulatory diseases (heart and blood vessel conditions) being the leading cause of death.
The solution lies in integrated diabetic and cardiac care, as diabetes is not just about blood sugar it is a chronic metabolic condition that progressively damages blood vessels, leading to blockages, heart attacks, strokes, and nerve damage (neuropathy) that affects heart rate regulation. Adults with diabetes are two to four times more likely to develop heart failure, making early intervention critical. At Daksh Diabetic & Cardiac Care, we provide affordable, quality assured medications for both diabetes management and heart protection, including SGLT2 inhibitors like DYFOZIN (Dapagliflozin) for heart and kidney protection, statins like ROSADAC (Rosuvastatin) for cholesterol control, ARBs like DYTEI (Telmisartan) for blood pressure management, and metformin like GLYCODIP SR for blood sugar control. With WHO-GMP certified quality and competitive pricing, Daksh empowers Delhi families through regular screening, medication adherence, lifestyle modifications, and early detection – ensuring thousands become success stories of integrated care and better health outcomes.
How Daksh is making a Difference in Delhi
1. Affordable, Quality-Assured Medications
Daksh Diabetic & Cardiac Care was established with a clear mission: to make quality pharmaceutical products available at affordable costs. As part of the Daksh Group of Companies which has over two decades of experience in the pharmaceutical industry the company brings credibility and trust to the diabetic and cardiac care segment.
What this means for Delhi patients:
- Access to WHO-GMP certified medications
- Lower out-of-pocket expenses for lifelong treatments
- No compromise on quality despite affordable pricing
2. Complete Cardiac Care Portfolio
Daksh offers a comprehensive range of cardiac care products that address the full spectrum of heart health needs:
| Product Category | Daksh Offerings | Purpose |
| ACE Inhibitors | DORAPIL (Ramipril) | Blood pressure control, heart failure treatment |
| ARBs | CARDIOVIL (Losartan), DYTEI (Telmisartan), OLMIDIP (Olmesartan) | Hypertension management |
| Beta-Blockers | CARDIOVIL (Carvedilol), METODIP (Metoprolol), NEBIDAC (Nebivolol) | Heart rate control, heart failure |
| Calcium Channel Blockers | DUPIN (Amlodipine), CLINITAC (Cilnidipine) | Blood pressure, angina |
| Diuretics | TORDAC (Torsemide), FRUSIDIP | Fluid management in heart failure |
| Lipid Management | ROSADAC (Rosuvastatin), ATRODAC (Atorvastatin) | Cholesterol control |
3. Complete Diabetic Care Portfolio
For diabetes management, Daksh provides modern therapeutic options including:
| Product Category | Daksh Offerings |
| SGLT2 Inhibitors | DYFOZIN (Dapagliflozin) – the modern heart-protective diabetes drug |
| DPP-4 Inhibitors | TENADAC (Teneligliptin), SITADAC (Sitagliptin), VILDADAC (Vildagliptin) |
| Sulfonylureas | GLIMIDAC (Glimepiride) |
| Biguanides | GLYCODIP SR (Metformin) |
| Combination Therapies | DYFOZIN M, GLIMIDAC MV (triple combination) |
4. Focus on Preventive Care
Daksh’s product portfolio includes nutritional supplements and preventive therapies that help patients maintain better health and avoid complications:
- Liver tonics for medication-induced liver protection
- Calcium supplements for bone health (critical for diabetic patients)
- Vitamin complexes for overall metabolic support
5. Supporting Healthcare Providers across Delhi
Daksh works with hospitals, clinics, and pharmacies across Delhi and the National Capital Region (NCR) to ensure that quality medications reach every corner of the capital. Through its PCD pharma franchise model, local entrepreneurs can partner with Daksh to serve their communities while building sustainable businesses. With the city’s high disease burden, a rapidly growing healthcare sector, and the advantage of monopoly rights to eliminate internal competition, there is immense potential to build a meaningful healthcare business while serving your community.
Conclusion
The diabetes and heart disease epidemic in Delhi is not just a statistic it is a reality affecting millions of families. With the national capital recording a 72.7% prevalence of diabetes or prediabetes, a hypertension prevalence of 35.7% in rural areas, and obesity rates exceeding 41%, the burden is immense and growing. But there is hope. With the right medications, proper awareness, and accessible healthcare, patients can live long, healthy, and fulfilling lives.
Daksh Diabetic & Cardiac Care is committed to being part of this solution providing affordable, quality-assured pharmaceutical products that align with the latest clinical guidelines.
Contact Daksh Diabetic and Cardiac
| Contact Method | Details |
| Office Address | Plot 249, Daksh House, Industrial Area Phase 2, Panchkula – 134109, Haryana, India |
| Phone | 📞 +91 93565 60523 📞 +91 78886 02869 |
| enquirypurchase.daksh@gmail.com | |
| Contact us | https://diabetes-cardiac.com/contact-us/ |